Global Biologics and Biosimilars Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
Summary
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
According to APO Research, The global Biologics and Biosimilars market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biologics and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biologics and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologics and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Biologics and Biosimilars sales, projected growth trends, production technology, application and end-user industry.
Biologics and Biosimilars segment by Company
1. To analyze and research the global Biologics and Biosimilars status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Biologics and Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Biologics and Biosimilars significant trends, drivers, influence factors in global and regions.
6. To analyze Biologics and Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Biologics and Biosimilars market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2019-2030).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics and Biosimilars industry.
Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Biologics and Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
According to APO Research, The global Biologics and Biosimilars market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biologics and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biologics and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologics and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Biologics and Biosimilars sales, projected growth trends, production technology, application and end-user industry.
Biologics and Biosimilars segment by Company
- Roche
- Amgen
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- 3sbio
- Changchun High Tech
- CP Guojian
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
- United Laboratories
- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Others
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global Biologics and Biosimilars status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Biologics and Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Biologics and Biosimilars significant trends, drivers, influence factors in global and regions.
6. To analyze Biologics and Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Biologics and Biosimilars market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2019-2030).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics and Biosimilars industry.
Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Biologics and Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Biologics and Biosimilars Sales Value (2019-2030)
1.2.2 Global Biologics and Biosimilars Sales Volume (2019-2030)
1.2.3 Global Biologics and Biosimilars Sales Average Price (2019-2030)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 BIOLOGICS AND BIOSIMILARS MARKET DYNAMICS
2.1 Biologics and Biosimilars Industry Trends
2.2 Biologics and Biosimilars Industry Drivers
2.3 Biologics and Biosimilars Industry Opportunities and Challenges
2.4 Biologics and Biosimilars Industry Restraints
3 BIOLOGICS AND BIOSIMILARS MARKET BY COMPANY
3.1 Global Biologics and Biosimilars Company Revenue Ranking in 2023
3.2 Global Biologics and Biosimilars Revenue by Company (2019-2024)
3.3 Global Biologics and Biosimilars Sales Volume by Company (2019-2024)
3.4 Global Biologics and Biosimilars Average Price by Company (2019-2024)
3.5 Global Biologics and Biosimilars Company Ranking, 2022 VS 2023 VS 2024
3.6 Global Biologics and Biosimilars Company Manufacturing Base & Headquarters
3.7 Global Biologics and Biosimilars Company, Product Type & Application
3.8 Global Biologics and Biosimilars Company Commercialization Time
3.9 Market Competitive Analysis
3.9.1 Global Biologics and Biosimilars Market CR5 and HHI
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.9.3 2023 Biologics and Biosimilars Tier 1, Tier 2, and Tier
3.10 Mergers & Acquisitions, Expansion
4 BIOLOGICS AND BIOSIMILARS MARKET BY TYPE
4.1 Biologics and Biosimilars Type Introduction
4.1.1 Monoclonal Antibodies
4.1.2 Interferon
4.1.3 Erythropoietin
4.1.4 Insulin
4.1.5 Vaccines
4.1.6 Others
4.2 Global Biologics and Biosimilars Sales Volume by Type
4.2.1 Global Biologics and Biosimilars Sales Volume by Type (2019 VS 2023 VS 2030)
4.2.2 Global Biologics and Biosimilars Sales Volume by Type (2019-2030)
4.2.3 Global Biologics and Biosimilars Sales Volume Share by Type (2019-2030)
4.3 Global Biologics and Biosimilars Sales Value by Type
4.3.1 Global Biologics and Biosimilars Sales Value by Type (2019 VS 2023 VS 2030)
4.3.2 Global Biologics and Biosimilars Sales Value by Type (2019-2030)
4.3.3 Global Biologics and Biosimilars Sales Value Share by Type (2019-2030)
5 BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION
5.1 Biologics and Biosimilars Application Introduction
5.1.1 Tumor
5.1.2 Diabetes
5.1.3 Cardiovascular
5.1.4 Hemophilia
5.1.5 Others
5.2 Global Biologics and Biosimilars Sales Volume by Application
5.2.1 Global Biologics and Biosimilars Sales Volume by Application (2019 VS 2023 VS 2030)
5.2.2 Global Biologics and Biosimilars Sales Volume by Application (2019-2030)
5.2.3 Global Biologics and Biosimilars Sales Volume Share by Application (2019-2030)
5.3 Global Biologics and Biosimilars Sales Value by Application
5.3.1 Global Biologics and Biosimilars Sales Value by Application (2019 VS 2023 VS 2030)
5.3.2 Global Biologics and Biosimilars Sales Value by Application (2019-2030)
5.3.3 Global Biologics and Biosimilars Sales Value Share by Application (2019-2030)
6 BIOLOGICS AND BIOSIMILARS MARKET BY REGION
6.1 Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Biologics and Biosimilars Sales by Region (2019-2030)
6.2.1 Global Biologics and Biosimilars Sales by Region: 2019-2024
6.2.2 Global Biologics and Biosimilars Sales by Region (2025-2030)
6.3 Global Biologics and Biosimilars Sales Value by Region: 2019 VS 2023 VS 2030
6.4 Global Biologics and Biosimilars Sales Value by Region (2019-2030)
6.4.1 Global Biologics and Biosimilars Sales Value by Region: 2019-2024
6.4.2 Global Biologics and Biosimilars Sales Value by Region (2025-2030)
6.5 Global Biologics and Biosimilars Market Price Analysis by Region (2019-2024)
6.6 North America
6.6.1 North America Biologics and Biosimilars Sales Value (2019-2030)
6.6.2 North America Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
6.7 Europe
6.7.1 Europe Biologics and Biosimilars Sales Value (2019-2030)
6.7.2 Europe Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
6.8 Asia-Pacific
6.8.1 Asia-Pacific Biologics and Biosimilars Sales Value (2019-2030)
6.8.2 Asia-Pacific Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
6.9 Latin America
6.9.1 Latin America Biologics and Biosimilars Sales Value (2019-2030)
6.9.2 Latin America Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
6.10 Middle East & Africa
6.10.1 Middle East & Africa Biologics and Biosimilars Sales Value (2019-2030)
6.10.2 Middle East & Africa Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
7 BIOLOGICS AND BIOSIMILARS MARKET BY COUNTRY
7.1 Global Biologics and Biosimilars Sales by Country: 2019 VS 2023 VS 2030
7.2 Global Biologics and Biosimilars Sales Value by Country: 2019 VS 2023 VS 2030
7.3 Global Biologics and Biosimilars Sales by Country (2019-2030)
7.3.1 Global Biologics and Biosimilars Sales by Country (2019-2024)
7.3.2 Global Biologics and Biosimilars Sales by Country (2025-2030)
7.4 Global Biologics and Biosimilars Sales Value by Country (2019-2030)
7.4.1 Global Biologics and Biosimilars Sales Value by Country (2019-2024)
7.4.2 Global Biologics and Biosimilars Sales Value by Country (2025-2030)
7.5 USA
7.5.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.5.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.6 Canada
7.6.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.6.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.7 Germany
7.7.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.7.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.8 France
7.8.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.8.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.9 U.K.
7.9.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.9.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.10 Italy
7.10.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.10.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.11 Netherlands
7.11.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.11.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.12 Nordic Countries
7.12.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.12.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.13 China
7.13.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.13.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.14 Japan
7.14.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.14.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.15 South Korea
7.15.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.15.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.16 Southeast Asia
7.16.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.16.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.17 India
7.17.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.17.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.18 Australia
7.18.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.18.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.19 Mexico
7.19.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.19.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.20 Brazil
7.20.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.20.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.21 Turkey
7.21.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.21.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.22 Saudi Arabia
7.22.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.22.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.22.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.23 UAE
7.23.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.23.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.23.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Roche
8.1.1 Roche Comapny Information
8.1.2 Roche Business Overview
8.1.3 Roche Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.1.4 Roche Biologics and Biosimilars Product Portfolio
8.1.5 Roche Recent Developments
8.2 Amgen
8.2.1 Amgen Comapny Information
8.2.2 Amgen Business Overview
8.2.3 Amgen Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.2.4 Amgen Biologics and Biosimilars Product Portfolio
8.2.5 Amgen Recent Developments
8.3 AbbVie
8.3.1 AbbVie Comapny Information
8.3.2 AbbVie Business Overview
8.3.3 AbbVie Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.3.4 AbbVie Biologics and Biosimilars Product Portfolio
8.3.5 AbbVie Recent Developments
8.4 Sanofi-Aventis
8.4.1 Sanofi-Aventis Comapny Information
8.4.2 Sanofi-Aventis Business Overview
8.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
8.4.5 Sanofi-Aventis Recent Developments
8.5 Johnson & Johnson
8.5.1 Johnson & Johnson Comapny Information
8.5.2 Johnson & Johnson Business Overview
8.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
8.5.5 Johnson & Johnson Recent Developments
8.6 Pfizer
8.6.1 Pfizer Comapny Information
8.6.2 Pfizer Business Overview
8.6.3 Pfizer Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.6.4 Pfizer Biologics and Biosimilars Product Portfolio
8.6.5 Pfizer Recent Developments
8.7 Novo Nordisk
8.7.1 Novo Nordisk Comapny Information
8.7.2 Novo Nordisk Business Overview
8.7.3 Novo Nordisk Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
8.7.5 Novo Nordisk Recent Developments
8.8 Eli Lilly
8.8.1 Eli Lilly Comapny Information
8.8.2 Eli Lilly Business Overview
8.8.3 Eli Lilly Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
8.8.5 Eli Lilly Recent Developments
8.9 Novartis
8.9.1 Novartis Comapny Information
8.9.2 Novartis Business Overview
8.9.3 Novartis Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.9.4 Novartis Biologics and Biosimilars Product Portfolio
8.9.5 Novartis Recent Developments
8.10 Merck
8.10.1 Merck Comapny Information
8.10.2 Merck Business Overview
8.10.3 Merck Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.10.4 Merck Biologics and Biosimilars Product Portfolio
8.10.5 Merck Recent Developments
8.11 3sbio
8.11.1 3sbio Comapny Information
8.11.2 3sbio Business Overview
8.11.3 3sbio Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.11.4 3sbio Biologics and Biosimilars Product Portfolio
8.11.5 3sbio Recent Developments
8.12 Changchun High Tech
8.12.1 Changchun High Tech Comapny Information
8.12.2 Changchun High Tech Business Overview
8.12.3 Changchun High Tech Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
8.12.5 Changchun High Tech Recent Developments
8.13 CP Guojian
8.13.1 CP Guojian Comapny Information
8.13.2 CP Guojian Business Overview
8.13.3 CP Guojian Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
8.13.5 CP Guojian Recent Developments
8.14 Biotech
8.14.1 Biotech Comapny Information
8.14.2 Biotech Business Overview
8.14.3 Biotech Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.14.4 Biotech Biologics and Biosimilars Product Portfolio
8.14.5 Biotech Recent Developments
8.15 Gelgen
8.15.1 Gelgen Comapny Information
8.15.2 Gelgen Business Overview
8.15.3 Gelgen Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.15.4 Gelgen Biologics and Biosimilars Product Portfolio
8.15.5 Gelgen Recent Developments
8.16 Innovent
8.16.1 Innovent Comapny Information
8.16.2 Innovent Business Overview
8.16.3 Innovent Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.16.4 Innovent Biologics and Biosimilars Product Portfolio
8.16.5 Innovent Recent Developments
8.17 Dong Bao
8.17.1 Dong Bao Comapny Information
8.17.2 Dong Bao Business Overview
8.17.3 Dong Bao Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
8.17.5 Dong Bao Recent Developments
8.18 Ganlee
8.18.1 Ganlee Comapny Information
8.18.2 Ganlee Business Overview
8.18.3 Ganlee Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.18.4 Ganlee Biologics and Biosimilars Product Portfolio
8.18.5 Ganlee Recent Developments
8.19 United Laboratories
8.19.1 United Laboratories Comapny Information
8.19.2 United Laboratories Business Overview
8.19.3 United Laboratories Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
8.19.5 United Laboratories Recent Developments
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Biologics and Biosimilars Value Chain Analysis
9.1.1 Biologics and Biosimilars Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Biologics and Biosimilars Sales Mode & Process
9.2 Biologics and Biosimilars Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Biologics and Biosimilars Distributors
9.2.3 Biologics and Biosimilars Customers
10 CONCLUDING INSIGHTS
11 APPENDIX
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Biologics and Biosimilars Sales Value (2019-2030)
1.2.2 Global Biologics and Biosimilars Sales Volume (2019-2030)
1.2.3 Global Biologics and Biosimilars Sales Average Price (2019-2030)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 BIOLOGICS AND BIOSIMILARS MARKET DYNAMICS
2.1 Biologics and Biosimilars Industry Trends
2.2 Biologics and Biosimilars Industry Drivers
2.3 Biologics and Biosimilars Industry Opportunities and Challenges
2.4 Biologics and Biosimilars Industry Restraints
3 BIOLOGICS AND BIOSIMILARS MARKET BY COMPANY
3.1 Global Biologics and Biosimilars Company Revenue Ranking in 2023
3.2 Global Biologics and Biosimilars Revenue by Company (2019-2024)
3.3 Global Biologics and Biosimilars Sales Volume by Company (2019-2024)
3.4 Global Biologics and Biosimilars Average Price by Company (2019-2024)
3.5 Global Biologics and Biosimilars Company Ranking, 2022 VS 2023 VS 2024
3.6 Global Biologics and Biosimilars Company Manufacturing Base & Headquarters
3.7 Global Biologics and Biosimilars Company, Product Type & Application
3.8 Global Biologics and Biosimilars Company Commercialization Time
3.9 Market Competitive Analysis
3.9.1 Global Biologics and Biosimilars Market CR5 and HHI
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.9.3 2023 Biologics and Biosimilars Tier 1, Tier 2, and Tier
3.10 Mergers & Acquisitions, Expansion
4 BIOLOGICS AND BIOSIMILARS MARKET BY TYPE
4.1 Biologics and Biosimilars Type Introduction
4.1.1 Monoclonal Antibodies
4.1.2 Interferon
4.1.3 Erythropoietin
4.1.4 Insulin
4.1.5 Vaccines
4.1.6 Others
4.2 Global Biologics and Biosimilars Sales Volume by Type
4.2.1 Global Biologics and Biosimilars Sales Volume by Type (2019 VS 2023 VS 2030)
4.2.2 Global Biologics and Biosimilars Sales Volume by Type (2019-2030)
4.2.3 Global Biologics and Biosimilars Sales Volume Share by Type (2019-2030)
4.3 Global Biologics and Biosimilars Sales Value by Type
4.3.1 Global Biologics and Biosimilars Sales Value by Type (2019 VS 2023 VS 2030)
4.3.2 Global Biologics and Biosimilars Sales Value by Type (2019-2030)
4.3.3 Global Biologics and Biosimilars Sales Value Share by Type (2019-2030)
5 BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION
5.1 Biologics and Biosimilars Application Introduction
5.1.1 Tumor
5.1.2 Diabetes
5.1.3 Cardiovascular
5.1.4 Hemophilia
5.1.5 Others
5.2 Global Biologics and Biosimilars Sales Volume by Application
5.2.1 Global Biologics and Biosimilars Sales Volume by Application (2019 VS 2023 VS 2030)
5.2.2 Global Biologics and Biosimilars Sales Volume by Application (2019-2030)
5.2.3 Global Biologics and Biosimilars Sales Volume Share by Application (2019-2030)
5.3 Global Biologics and Biosimilars Sales Value by Application
5.3.1 Global Biologics and Biosimilars Sales Value by Application (2019 VS 2023 VS 2030)
5.3.2 Global Biologics and Biosimilars Sales Value by Application (2019-2030)
5.3.3 Global Biologics and Biosimilars Sales Value Share by Application (2019-2030)
6 BIOLOGICS AND BIOSIMILARS MARKET BY REGION
6.1 Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Biologics and Biosimilars Sales by Region (2019-2030)
6.2.1 Global Biologics and Biosimilars Sales by Region: 2019-2024
6.2.2 Global Biologics and Biosimilars Sales by Region (2025-2030)
6.3 Global Biologics and Biosimilars Sales Value by Region: 2019 VS 2023 VS 2030
6.4 Global Biologics and Biosimilars Sales Value by Region (2019-2030)
6.4.1 Global Biologics and Biosimilars Sales Value by Region: 2019-2024
6.4.2 Global Biologics and Biosimilars Sales Value by Region (2025-2030)
6.5 Global Biologics and Biosimilars Market Price Analysis by Region (2019-2024)
6.6 North America
6.6.1 North America Biologics and Biosimilars Sales Value (2019-2030)
6.6.2 North America Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
6.7 Europe
6.7.1 Europe Biologics and Biosimilars Sales Value (2019-2030)
6.7.2 Europe Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
6.8 Asia-Pacific
6.8.1 Asia-Pacific Biologics and Biosimilars Sales Value (2019-2030)
6.8.2 Asia-Pacific Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
6.9 Latin America
6.9.1 Latin America Biologics and Biosimilars Sales Value (2019-2030)
6.9.2 Latin America Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
6.10 Middle East & Africa
6.10.1 Middle East & Africa Biologics and Biosimilars Sales Value (2019-2030)
6.10.2 Middle East & Africa Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
7 BIOLOGICS AND BIOSIMILARS MARKET BY COUNTRY
7.1 Global Biologics and Biosimilars Sales by Country: 2019 VS 2023 VS 2030
7.2 Global Biologics and Biosimilars Sales Value by Country: 2019 VS 2023 VS 2030
7.3 Global Biologics and Biosimilars Sales by Country (2019-2030)
7.3.1 Global Biologics and Biosimilars Sales by Country (2019-2024)
7.3.2 Global Biologics and Biosimilars Sales by Country (2025-2030)
7.4 Global Biologics and Biosimilars Sales Value by Country (2019-2030)
7.4.1 Global Biologics and Biosimilars Sales Value by Country (2019-2024)
7.4.2 Global Biologics and Biosimilars Sales Value by Country (2025-2030)
7.5 USA
7.5.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.5.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.6 Canada
7.6.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.6.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.7 Germany
7.7.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.7.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.8 France
7.8.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.8.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.9 U.K.
7.9.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.9.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.10 Italy
7.10.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.10.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.11 Netherlands
7.11.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.11.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.12 Nordic Countries
7.12.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.12.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.13 China
7.13.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.13.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.14 Japan
7.14.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.14.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.15 South Korea
7.15.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.15.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.16 Southeast Asia
7.16.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.16.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.17 India
7.17.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.17.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.18 Australia
7.18.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.18.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.19 Mexico
7.19.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.19.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.20 Brazil
7.20.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.20.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.21 Turkey
7.21.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.21.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.22 Saudi Arabia
7.22.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.22.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.22.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
7.23 UAE
7.23.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
7.23.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
7.23.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Roche
8.1.1 Roche Comapny Information
8.1.2 Roche Business Overview
8.1.3 Roche Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.1.4 Roche Biologics and Biosimilars Product Portfolio
8.1.5 Roche Recent Developments
8.2 Amgen
8.2.1 Amgen Comapny Information
8.2.2 Amgen Business Overview
8.2.3 Amgen Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.2.4 Amgen Biologics and Biosimilars Product Portfolio
8.2.5 Amgen Recent Developments
8.3 AbbVie
8.3.1 AbbVie Comapny Information
8.3.2 AbbVie Business Overview
8.3.3 AbbVie Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.3.4 AbbVie Biologics and Biosimilars Product Portfolio
8.3.5 AbbVie Recent Developments
8.4 Sanofi-Aventis
8.4.1 Sanofi-Aventis Comapny Information
8.4.2 Sanofi-Aventis Business Overview
8.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
8.4.5 Sanofi-Aventis Recent Developments
8.5 Johnson & Johnson
8.5.1 Johnson & Johnson Comapny Information
8.5.2 Johnson & Johnson Business Overview
8.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
8.5.5 Johnson & Johnson Recent Developments
8.6 Pfizer
8.6.1 Pfizer Comapny Information
8.6.2 Pfizer Business Overview
8.6.3 Pfizer Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.6.4 Pfizer Biologics and Biosimilars Product Portfolio
8.6.5 Pfizer Recent Developments
8.7 Novo Nordisk
8.7.1 Novo Nordisk Comapny Information
8.7.2 Novo Nordisk Business Overview
8.7.3 Novo Nordisk Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
8.7.5 Novo Nordisk Recent Developments
8.8 Eli Lilly
8.8.1 Eli Lilly Comapny Information
8.8.2 Eli Lilly Business Overview
8.8.3 Eli Lilly Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
8.8.5 Eli Lilly Recent Developments
8.9 Novartis
8.9.1 Novartis Comapny Information
8.9.2 Novartis Business Overview
8.9.3 Novartis Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.9.4 Novartis Biologics and Biosimilars Product Portfolio
8.9.5 Novartis Recent Developments
8.10 Merck
8.10.1 Merck Comapny Information
8.10.2 Merck Business Overview
8.10.3 Merck Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.10.4 Merck Biologics and Biosimilars Product Portfolio
8.10.5 Merck Recent Developments
8.11 3sbio
8.11.1 3sbio Comapny Information
8.11.2 3sbio Business Overview
8.11.3 3sbio Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.11.4 3sbio Biologics and Biosimilars Product Portfolio
8.11.5 3sbio Recent Developments
8.12 Changchun High Tech
8.12.1 Changchun High Tech Comapny Information
8.12.2 Changchun High Tech Business Overview
8.12.3 Changchun High Tech Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
8.12.5 Changchun High Tech Recent Developments
8.13 CP Guojian
8.13.1 CP Guojian Comapny Information
8.13.2 CP Guojian Business Overview
8.13.3 CP Guojian Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
8.13.5 CP Guojian Recent Developments
8.14 Biotech
8.14.1 Biotech Comapny Information
8.14.2 Biotech Business Overview
8.14.3 Biotech Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.14.4 Biotech Biologics and Biosimilars Product Portfolio
8.14.5 Biotech Recent Developments
8.15 Gelgen
8.15.1 Gelgen Comapny Information
8.15.2 Gelgen Business Overview
8.15.3 Gelgen Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.15.4 Gelgen Biologics and Biosimilars Product Portfolio
8.15.5 Gelgen Recent Developments
8.16 Innovent
8.16.1 Innovent Comapny Information
8.16.2 Innovent Business Overview
8.16.3 Innovent Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.16.4 Innovent Biologics and Biosimilars Product Portfolio
8.16.5 Innovent Recent Developments
8.17 Dong Bao
8.17.1 Dong Bao Comapny Information
8.17.2 Dong Bao Business Overview
8.17.3 Dong Bao Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
8.17.5 Dong Bao Recent Developments
8.18 Ganlee
8.18.1 Ganlee Comapny Information
8.18.2 Ganlee Business Overview
8.18.3 Ganlee Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.18.4 Ganlee Biologics and Biosimilars Product Portfolio
8.18.5 Ganlee Recent Developments
8.19 United Laboratories
8.19.1 United Laboratories Comapny Information
8.19.2 United Laboratories Business Overview
8.19.3 United Laboratories Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
8.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
8.19.5 United Laboratories Recent Developments
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Biologics and Biosimilars Value Chain Analysis
9.1.1 Biologics and Biosimilars Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Biologics and Biosimilars Sales Mode & Process
9.2 Biologics and Biosimilars Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Biologics and Biosimilars Distributors
9.2.3 Biologics and Biosimilars Customers
10 CONCLUDING INSIGHTS
11 APPENDIX
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
LIST OF TABLES
Table 1. Biologics and Biosimilars Industry Trends
Table 2. Biologics and Biosimilars Industry Drivers
Table 3. Biologics and Biosimilars Industry Opportunities and Challenges
Table 4. Biologics and Biosimilars Industry Restraints
Table 5. Global Biologics and Biosimilars Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Biologics and Biosimilars Revenue Share by Company (2019-2024)
Table 7. Global Biologics and Biosimilars Sales Volume by Company (K Units) & (2019-2024)
Table 8. Global Biologics and Biosimilars Sales Volume Share by Company (2019-2024)
Table 9. Global Biologics and Biosimilars Average Price (USD/Unit) of Company (2019-2024)
Table 10. Global Biologics and Biosimilars Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 11. Global Biologics and Biosimilars Key Company Manufacturing Base & Headquarters
Table 12. Global Biologics and Biosimilars Company, Product Type & Application
Table 13. Global Biologics and Biosimilars Company Commercialization Time
Table 14. Global Company Market Concentration Ratio (CR5 and HHI)
Table 15. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 16. Mergers & Acquisitions, Expansion
Table 17. Major Companies of Monoclonal Antibodies
Table 18. Major Companies of Interferon
Table 19. Major Companies of Erythropoietin
Table 20. Major Companies of Insulin
Table 21. Major Companies of Vaccines
Table 22. Major Companies of Others
Table 23. Global Biologics and Biosimilars Sales Volume by Type 2019 VS 2023 VS 2030 (K Units)
Table 24. Global Biologics and Biosimilars Sales Volume by Type (2019-2024) & (K Units)
Table 25. Global Biologics and Biosimilars Sales Volume by Type (2025-2030) & (K Units)
Table 26. Global Biologics and Biosimilars Sales Volume Share by Type (2019-2024)
Table 27. Global Biologics and Biosimilars Sales Volume Share by Type (2025-2030)
Table 28. Global Biologics and Biosimilars Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Biologics and Biosimilars Sales Value by Type (2019-2024) & (US$ Million)
Table 30. Global Biologics and Biosimilars Sales Value by Type (2025-2030) & (US$ Million)
Table 31. Global Biologics and Biosimilars Sales Value Share by Type (2019-2024)
Table 32. Global Biologics and Biosimilars Sales Value Share by Type (2025-2030)
Table 33. Major Companies of Tumor
Table 34. Major Companies of Diabetes
Table 35. Major Companies of Cardiovascular
Table 36. Major Companies of Hemophilia
Table 37. Major Companies of Others
Table 38. Global Biologics and Biosimilars Sales Volume by Application 2019 VS 2023 VS 2030 (K Units)
Table 39. Global Biologics and Biosimilars Sales Volume by Application (2019-2024) & (K Units)
Table 40. Global Biologics and Biosimilars Sales Volume by Application (2025-2030) & (K Units)
Table 41. Global Biologics and Biosimilars Sales Volume Share by Application (2019-2024)
Table 42. Global Biologics and Biosimilars Sales Volume Share by Application (2025-2030)
Table 43. Global Biologics and Biosimilars Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 44. Global Biologics and Biosimilars Sales Value by Application (2019-2024) & (US$ Million)
Table 45. Global Biologics and Biosimilars Sales Value by Application (2025-2030) & (US$ Million)
Table 46. Global Biologics and Biosimilars Sales Value Share by Application (2019-2024)
Table 47. Global Biologics and Biosimilars Sales Value Share by Application (2025-2030)
Table 48. Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030 (K Units)
Table 49. Global Biologics and Biosimilars Sales by Region (2019-2024) & (K Units)
Table 50. Global Biologics and Biosimilars Sales Market Share by Region (2019-2024)
Table 51. Global Biologics and Biosimilars Sales by Region (2025-2030) & (K Units)
Table 52. Global Biologics and Biosimilars Sales Market Share by Region (2025-2030)
Table 53. Global Biologics and Biosimilars Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 54. Global Biologics and Biosimilars Sales Value by Region (2019-2024) & (US$ Million)
Table 55. Global Biologics and Biosimilars Sales Value Share by Region (2019-2024)
Table 56. Global Biologics and Biosimilars Sales Value by Region (2025-2030) & (US$ Million)
Table 57. Global Biologics and Biosimilars Sales Value Share by Region (2025-2030)
Table 58. Global Biologics and Biosimilars Market Average Price (USD/Unit) by Region (2019-2024)
Table 59. Global Biologics and Biosimilars Market Average Price (USD/Unit) by Region (2025-2030)
Table 60. Global Biologics and Biosimilars Sales by Country: 2019 VS 2023 VS 2030 (K Units)
Table 61. Global Biologics and Biosimilars Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 62. Global Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 63. Global Biologics and Biosimilars Sales Market Share by Country (2019-2024)
Table 64. Global Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
Table 65. Global Biologics and Biosimilars Sales Market Share by Country (2025-2030)
Table 66. Global Biologics and Biosimilars Sales Value by Country (2019-2024) & (US$ Million)
Table 67. Global Biologics and Biosimilars Sales Value Market Share by Country (2019-2024)
Table 68. Global Biologics and Biosimilars Sales Value by Country (2025-2030) & (US$ Million)
Table 69. Global Biologics and Biosimilars Sales Value Market Share by Country (2025-2030)
Table 70. Roche Company Information
Table 71. Roche Business Overview
Table 72. Roche Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Roche Biologics and Biosimilars Product Portfolio
Table 74. Roche Recent Development
Table 75. Amgen Company Information
Table 76. Amgen Business Overview
Table 77. Amgen Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Amgen Biologics and Biosimilars Product Portfolio
Table 79. Amgen Recent Development
Table 80. AbbVie Company Information
Table 81. AbbVie Business Overview
Table 82. AbbVie Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. AbbVie Biologics and Biosimilars Product Portfolio
Table 84. AbbVie Recent Development
Table 85. Sanofi-Aventis Company Information
Table 86. Sanofi-Aventis Business Overview
Table 87. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Sanofi-Aventis Biologics and Biosimilars Product Portfolio
Table 89. Sanofi-Aventis Recent Development
Table 90. Johnson & Johnson Company Information
Table 91. Johnson & Johnson Business Overview
Table 92. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Johnson & Johnson Biologics and Biosimilars Product Portfolio
Table 94. Johnson & Johnson Recent Development
Table 95. Pfizer Company Information
Table 96. Pfizer Business Overview
Table 97. Pfizer Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Pfizer Biologics and Biosimilars Product Portfolio
Table 99. Pfizer Recent Development
Table 100. Novo Nordisk Company Information
Table 101. Novo Nordisk Business Overview
Table 102. Novo Nordisk Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Novo Nordisk Biologics and Biosimilars Product Portfolio
Table 104. Novo Nordisk Recent Development
Table 105. Eli Lilly Company Information
Table 106. Eli Lilly Business Overview
Table 107. Eli Lilly Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Eli Lilly Biologics and Biosimilars Product Portfolio
Table 109. Eli Lilly Recent Development
Table 110. Novartis Company Information
Table 111. Novartis Business Overview
Table 112. Novartis Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Novartis Biologics and Biosimilars Product Portfolio
Table 114. Novartis Recent Development
Table 115. Merck Company Information
Table 116. Merck Business Overview
Table 117. Merck Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. Merck Biologics and Biosimilars Product Portfolio
Table 119. Merck Recent Development
Table 120. 3sbio Company Information
Table 121. 3sbio Business Overview
Table 122. 3sbio Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 123. 3sbio Biologics and Biosimilars Product Portfolio
Table 124. 3sbio Recent Development
Table 125. Changchun High Tech Company Information
Table 126. Changchun High Tech Business Overview
Table 127. Changchun High Tech Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 128. Changchun High Tech Biologics and Biosimilars Product Portfolio
Table 129. Changchun High Tech Recent Development
Table 130. CP Guojian Company Information
Table 131. CP Guojian Business Overview
Table 132. CP Guojian Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 133. CP Guojian Biologics and Biosimilars Product Portfolio
Table 134. CP Guojian Recent Development
Table 135. Biotech Company Information
Table 136. Biotech Business Overview
Table 137. Biotech Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 138. Biotech Biologics and Biosimilars Product Portfolio
Table 139. Biotech Recent Development
Table 140. Gelgen Company Information
Table 141. Gelgen Business Overview
Table 142. Gelgen Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 143. Gelgen Biologics and Biosimilars Product Portfolio
Table 144. Gelgen Recent Development
Table 145. Innovent Company Information
Table 146. Innovent Business Overview
Table 147. Innovent Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 148. Innovent Biologics and Biosimilars Product Portfolio
Table 149. Innovent Recent Development
Table 150. Dong Bao Company Information
Table 151. Dong Bao Business Overview
Table 152. Dong Bao Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 153. Dong Bao Biologics and Biosimilars Product Portfolio
Table 154. Dong Bao Recent Development
Table 155. Ganlee Company Information
Table 156. Ganlee Business Overview
Table 157. Ganlee Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 158. Ganlee Biologics and Biosimilars Product Portfolio
Table 159. Ganlee Recent Development
Table 160. United Laboratories Company Information
Table 161. United Laboratories Business Overview
Table 162. United Laboratories Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 163. United Laboratories Biologics and Biosimilars Product Portfolio
Table 164. United Laboratories Recent Development
Table 165. Key Raw Materials
Table 166. Raw Materials Key Suppliers
Table 167. Biologics and Biosimilars Distributors List
Table 168. Biologics and Biosimilars Customers List
Table 169. Research Programs/Design for This Report
Table 170. Authors List of This Report
Table 171. Secondary Sources
Table 172. Primary Sources
Table 1. Biologics and Biosimilars Industry Trends
Table 2. Biologics and Biosimilars Industry Drivers
Table 3. Biologics and Biosimilars Industry Opportunities and Challenges
Table 4. Biologics and Biosimilars Industry Restraints
Table 5. Global Biologics and Biosimilars Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Biologics and Biosimilars Revenue Share by Company (2019-2024)
Table 7. Global Biologics and Biosimilars Sales Volume by Company (K Units) & (2019-2024)
Table 8. Global Biologics and Biosimilars Sales Volume Share by Company (2019-2024)
Table 9. Global Biologics and Biosimilars Average Price (USD/Unit) of Company (2019-2024)
Table 10. Global Biologics and Biosimilars Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 11. Global Biologics and Biosimilars Key Company Manufacturing Base & Headquarters
Table 12. Global Biologics and Biosimilars Company, Product Type & Application
Table 13. Global Biologics and Biosimilars Company Commercialization Time
Table 14. Global Company Market Concentration Ratio (CR5 and HHI)
Table 15. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 16. Mergers & Acquisitions, Expansion
Table 17. Major Companies of Monoclonal Antibodies
Table 18. Major Companies of Interferon
Table 19. Major Companies of Erythropoietin
Table 20. Major Companies of Insulin
Table 21. Major Companies of Vaccines
Table 22. Major Companies of Others
Table 23. Global Biologics and Biosimilars Sales Volume by Type 2019 VS 2023 VS 2030 (K Units)
Table 24. Global Biologics and Biosimilars Sales Volume by Type (2019-2024) & (K Units)
Table 25. Global Biologics and Biosimilars Sales Volume by Type (2025-2030) & (K Units)
Table 26. Global Biologics and Biosimilars Sales Volume Share by Type (2019-2024)
Table 27. Global Biologics and Biosimilars Sales Volume Share by Type (2025-2030)
Table 28. Global Biologics and Biosimilars Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Biologics and Biosimilars Sales Value by Type (2019-2024) & (US$ Million)
Table 30. Global Biologics and Biosimilars Sales Value by Type (2025-2030) & (US$ Million)
Table 31. Global Biologics and Biosimilars Sales Value Share by Type (2019-2024)
Table 32. Global Biologics and Biosimilars Sales Value Share by Type (2025-2030)
Table 33. Major Companies of Tumor
Table 34. Major Companies of Diabetes
Table 35. Major Companies of Cardiovascular
Table 36. Major Companies of Hemophilia
Table 37. Major Companies of Others
Table 38. Global Biologics and Biosimilars Sales Volume by Application 2019 VS 2023 VS 2030 (K Units)
Table 39. Global Biologics and Biosimilars Sales Volume by Application (2019-2024) & (K Units)
Table 40. Global Biologics and Biosimilars Sales Volume by Application (2025-2030) & (K Units)
Table 41. Global Biologics and Biosimilars Sales Volume Share by Application (2019-2024)
Table 42. Global Biologics and Biosimilars Sales Volume Share by Application (2025-2030)
Table 43. Global Biologics and Biosimilars Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 44. Global Biologics and Biosimilars Sales Value by Application (2019-2024) & (US$ Million)
Table 45. Global Biologics and Biosimilars Sales Value by Application (2025-2030) & (US$ Million)
Table 46. Global Biologics and Biosimilars Sales Value Share by Application (2019-2024)
Table 47. Global Biologics and Biosimilars Sales Value Share by Application (2025-2030)
Table 48. Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030 (K Units)
Table 49. Global Biologics and Biosimilars Sales by Region (2019-2024) & (K Units)
Table 50. Global Biologics and Biosimilars Sales Market Share by Region (2019-2024)
Table 51. Global Biologics and Biosimilars Sales by Region (2025-2030) & (K Units)
Table 52. Global Biologics and Biosimilars Sales Market Share by Region (2025-2030)
Table 53. Global Biologics and Biosimilars Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 54. Global Biologics and Biosimilars Sales Value by Region (2019-2024) & (US$ Million)
Table 55. Global Biologics and Biosimilars Sales Value Share by Region (2019-2024)
Table 56. Global Biologics and Biosimilars Sales Value by Region (2025-2030) & (US$ Million)
Table 57. Global Biologics and Biosimilars Sales Value Share by Region (2025-2030)
Table 58. Global Biologics and Biosimilars Market Average Price (USD/Unit) by Region (2019-2024)
Table 59. Global Biologics and Biosimilars Market Average Price (USD/Unit) by Region (2025-2030)
Table 60. Global Biologics and Biosimilars Sales by Country: 2019 VS 2023 VS 2030 (K Units)
Table 61. Global Biologics and Biosimilars Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 62. Global Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 63. Global Biologics and Biosimilars Sales Market Share by Country (2019-2024)
Table 64. Global Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
Table 65. Global Biologics and Biosimilars Sales Market Share by Country (2025-2030)
Table 66. Global Biologics and Biosimilars Sales Value by Country (2019-2024) & (US$ Million)
Table 67. Global Biologics and Biosimilars Sales Value Market Share by Country (2019-2024)
Table 68. Global Biologics and Biosimilars Sales Value by Country (2025-2030) & (US$ Million)
Table 69. Global Biologics and Biosimilars Sales Value Market Share by Country (2025-2030)
Table 70. Roche Company Information
Table 71. Roche Business Overview
Table 72. Roche Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Roche Biologics and Biosimilars Product Portfolio
Table 74. Roche Recent Development
Table 75. Amgen Company Information
Table 76. Amgen Business Overview
Table 77. Amgen Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Amgen Biologics and Biosimilars Product Portfolio
Table 79. Amgen Recent Development
Table 80. AbbVie Company Information
Table 81. AbbVie Business Overview
Table 82. AbbVie Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. AbbVie Biologics and Biosimilars Product Portfolio
Table 84. AbbVie Recent Development
Table 85. Sanofi-Aventis Company Information
Table 86. Sanofi-Aventis Business Overview
Table 87. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Sanofi-Aventis Biologics and Biosimilars Product Portfolio
Table 89. Sanofi-Aventis Recent Development
Table 90. Johnson & Johnson Company Information
Table 91. Johnson & Johnson Business Overview
Table 92. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Johnson & Johnson Biologics and Biosimilars Product Portfolio
Table 94. Johnson & Johnson Recent Development
Table 95. Pfizer Company Information
Table 96. Pfizer Business Overview
Table 97. Pfizer Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Pfizer Biologics and Biosimilars Product Portfolio
Table 99. Pfizer Recent Development
Table 100. Novo Nordisk Company Information
Table 101. Novo Nordisk Business Overview
Table 102. Novo Nordisk Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Novo Nordisk Biologics and Biosimilars Product Portfolio
Table 104. Novo Nordisk Recent Development
Table 105. Eli Lilly Company Information
Table 106. Eli Lilly Business Overview
Table 107. Eli Lilly Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Eli Lilly Biologics and Biosimilars Product Portfolio
Table 109. Eli Lilly Recent Development
Table 110. Novartis Company Information
Table 111. Novartis Business Overview
Table 112. Novartis Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Novartis Biologics and Biosimilars Product Portfolio
Table 114. Novartis Recent Development
Table 115. Merck Company Information
Table 116. Merck Business Overview
Table 117. Merck Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. Merck Biologics and Biosimilars Product Portfolio
Table 119. Merck Recent Development
Table 120. 3sbio Company Information
Table 121. 3sbio Business Overview
Table 122. 3sbio Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 123. 3sbio Biologics and Biosimilars Product Portfolio
Table 124. 3sbio Recent Development
Table 125. Changchun High Tech Company Information
Table 126. Changchun High Tech Business Overview
Table 127. Changchun High Tech Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 128. Changchun High Tech Biologics and Biosimilars Product Portfolio
Table 129. Changchun High Tech Recent Development
Table 130. CP Guojian Company Information
Table 131. CP Guojian Business Overview
Table 132. CP Guojian Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 133. CP Guojian Biologics and Biosimilars Product Portfolio
Table 134. CP Guojian Recent Development
Table 135. Biotech Company Information
Table 136. Biotech Business Overview
Table 137. Biotech Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 138. Biotech Biologics and Biosimilars Product Portfolio
Table 139. Biotech Recent Development
Table 140. Gelgen Company Information
Table 141. Gelgen Business Overview
Table 142. Gelgen Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 143. Gelgen Biologics and Biosimilars Product Portfolio
Table 144. Gelgen Recent Development
Table 145. Innovent Company Information
Table 146. Innovent Business Overview
Table 147. Innovent Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 148. Innovent Biologics and Biosimilars Product Portfolio
Table 149. Innovent Recent Development
Table 150. Dong Bao Company Information
Table 151. Dong Bao Business Overview
Table 152. Dong Bao Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 153. Dong Bao Biologics and Biosimilars Product Portfolio
Table 154. Dong Bao Recent Development
Table 155. Ganlee Company Information
Table 156. Ganlee Business Overview
Table 157. Ganlee Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 158. Ganlee Biologics and Biosimilars Product Portfolio
Table 159. Ganlee Recent Development
Table 160. United Laboratories Company Information
Table 161. United Laboratories Business Overview
Table 162. United Laboratories Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 163. United Laboratories Biologics and Biosimilars Product Portfolio
Table 164. United Laboratories Recent Development
Table 165. Key Raw Materials
Table 166. Raw Materials Key Suppliers
Table 167. Biologics and Biosimilars Distributors List
Table 168. Biologics and Biosimilars Customers List
Table 169. Research Programs/Design for This Report
Table 170. Authors List of This Report
Table 171. Secondary Sources
Table 172. Primary Sources
LIST OF FIGURES
Figure 1. Biologics and Biosimilars Product Picture
Figure 2. Global Biologics and Biosimilars Sales Value (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Biologics and Biosimilars Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Biologics and Biosimilars Sales (2019-2030) & (K Units)
Figure 5. Global Biologics and Biosimilars Sales Average Price (USD/Unit) & (2019-2030)
Figure 6. Global Biologics and Biosimilars Company Revenue Ranking in 2023 (US$ Million)
Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 9. Monoclonal Antibodies Picture
Figure 10. Interferon Picture
Figure 11. Erythropoietin Picture
Figure 12. Insulin Picture
Figure 13. Vaccines Picture
Figure 14. Others Picture
Figure 15. Global Biologics and Biosimilars Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 16. Global Biologics and Biosimilars Sales Volume Share 2019 VS 2023 VS 2030
Figure 17. Global Biologics and Biosimilars Sales Volume Share by Type (2019-2030)
Figure 18. Global Biologics and Biosimilars Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Biologics and Biosimilars Sales Value Share 2019 VS 2023 VS 2030
Figure 20. Global Biologics and Biosimilars Sales Value Share by Type (2019-2030)
Figure 21. Tumor Picture
Figure 22. Diabetes Picture
Figure 23. Cardiovascular Picture
Figure 24. Hemophilia Picture
Figure 25. Others Picture
Figure 26. Global Biologics and Biosimilars Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 27. Global Biologics and Biosimilars Sales Volume Share 2019 VS 2023 VS 2030
Figure 28. Global Biologics an
Figure 1. Biologics and Biosimilars Product Picture
Figure 2. Global Biologics and Biosimilars Sales Value (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Biologics and Biosimilars Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Biologics and Biosimilars Sales (2019-2030) & (K Units)
Figure 5. Global Biologics and Biosimilars Sales Average Price (USD/Unit) & (2019-2030)
Figure 6. Global Biologics and Biosimilars Company Revenue Ranking in 2023 (US$ Million)
Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 9. Monoclonal Antibodies Picture
Figure 10. Interferon Picture
Figure 11. Erythropoietin Picture
Figure 12. Insulin Picture
Figure 13. Vaccines Picture
Figure 14. Others Picture
Figure 15. Global Biologics and Biosimilars Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 16. Global Biologics and Biosimilars Sales Volume Share 2019 VS 2023 VS 2030
Figure 17. Global Biologics and Biosimilars Sales Volume Share by Type (2019-2030)
Figure 18. Global Biologics and Biosimilars Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Biologics and Biosimilars Sales Value Share 2019 VS 2023 VS 2030
Figure 20. Global Biologics and Biosimilars Sales Value Share by Type (2019-2030)
Figure 21. Tumor Picture
Figure 22. Diabetes Picture
Figure 23. Cardiovascular Picture
Figure 24. Hemophilia Picture
Figure 25. Others Picture
Figure 26. Global Biologics and Biosimilars Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 27. Global Biologics and Biosimilars Sales Volume Share 2019 VS 2023 VS 2030
Figure 28. Global Biologics an
